Florquinitau F 18 PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Tau-targeted fluorine-18 radiopharmaceuticaldiagnostic PET imaging agent
Mechanism of action
Binds to aggregated tau protein in the brain, including tau neurofibrillary tangles. After intravenous administration it crosses the blood-brain barrier and accumulates in regions containing tau aggregates; fluorine-18 positron emissions permit PET visualisation.
Indications / reported uses
PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary-tangle pathology, under the US TAUKLARIFY product indication.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Florquinitau F 18 PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Florquinitau F 18 Permitted Daily Exposure (PDE) report (the Florquinitau F 18 PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Florquinitau F 18 Occupational Exposure Limit (OEL) report (the Florquinitau F 18 OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.